Miriam Bach
Overview
Explore the profile of Miriam Bach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kirchhof P, Haas S, Amarenco P, Turpie A, Bach M, Lambelet M, et al.
Europace
. 2024 Jun;
26(7).
PMID: 38941511
Aims: Anticoagulation can prevent stroke and prolong lives in patients with atrial fibrillation (AF). However, anticoagulated patients with AF remain at risk of death. The aim of this study was...
2.
Maraveyas A, Beyer-Westendorf J, Lee A, Mantovani L, De Sanctis Y, Abdelgawwad K, et al.
Res Pract Thromb Haemost
. 2021 Dec;
5(8):e12604.
PMID: 34877446
Background: Patients with cancer-associated thrombosis (CAT) have a high risk of recurrent venous thromboembolic events, which contribute to significant morbidity and mortality. Direct oral anticoagulants may provide a convenient treatment...
3.
Sebastian T, Bach M, Geiger A, Lusiola T, Kozielski L, Clemens F
Materials (Basel)
. 2021 Oct;
14(20).
PMID: 34683518
Piezoelectric composites with 3-3 connectivity gathered attraction due to their potential application as an acoustic transducer in medical imaging, non-destructive testing, etc. In this contribution, piezoelectric composites were fabricated with...
4.
Cohen A, Maraveyas A, Beyer-Westendorf J, Lee A, Folkerts K, Abdelgawwad K, et al.
Thromb Res
. 2021 Jul;
206:1-4.
PMID: 34332213
No abstract available.
5.
Camm A, Amarenco P, Haas S, Bach M, Kirchhof P, Kuhls S, et al.
Clin Cardiol
. 2020 Sep;
43(12):1405-1413.
PMID: 32896928
Background: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events...
6.
Picker N, Lee A, Cohen A, Maraveyas A, Beyer-Westendorf J, Mantovani L, et al.
Thromb Haemost
. 2020 Sep;
121(2):206-215.
PMID: 32877956
Introduction: Clinical guidelines recommend anticoagulation therapy for the treatment of cancer-associated venous thromboembolism (VTE), but little is known about preferences. Therefore, the objective of this discrete choice experiment (DCE) was...
7.
Kirchhof P, Bach M, Camm A
J Am Coll Cardiol
. 2018 Nov;
72(20):2546-2547.
PMID: 30442303
No abstract available.
8.
Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, et al.
Eur Heart J Cardiovasc Pharmacother
. 2018 Nov;
5(2):70-79.
PMID: 30423165
Aims: In Europe, the approved rivaroxaban dose for stroke prevention in patients with atrial fibrillation (AF) is 20 mg once daily (o.d.), with 15 mg o.d. recommended in patients with...
9.
Cohen A, Maraveyas A, Beyer-Westendorf J, Lee A, Mantovani L, Bach M
Thromb J
. 2018 Sep;
16:21.
PMID: 30186045
Background: Around 20% of venous thromboembolism (VTE) cases occur in patients with cancer. Current guidelines recommend low molecular weight heparin (LMWH) as the preferred anticoagulant for VTE treatment. However, some...
10.
Camm A, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, et al.
Europace
. 2018 Jul;
21(3):421-427.
PMID: 30052894
Aims: Based on Phase III data, non-vitamin K antagonist oral anticoagulants are recommended for stroke prevention in patients with atrial fibrillation. To determine whether trial outcomes translate into similar event...